FDA approves biosimilar to J&J's Remicade for multiple diseases

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson's drug Remicade, to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine.